Woodline Partners’s Immuneering IMRX Stock Holding History

Woodline Partners’s Portfolio IMRX Stock Details IMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-150,000	Closed	-$987K	–	1097
2025 Q4	$987K	Hold	150,000	–	–	﹤0.01%	841
2025 Q3	$1.05M	Buy	+150,000	New	+$778K	﹤0.01%	799

Other funds holding IMRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

OCM

Occam Crest Management Darien, Connecticut $165M AUM

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Woodline Partners's IMRX Position: Q1 2026 in Review

Woodline Partners sold out of Immuneering (IMRX) in Q1 2026, closing a stake of 150,000 shares — an estimated $987K sold.

Woodline Partners first reported a position in IMRX in Q3 2025 and held it in 2 quarters. The position peaked at $1.05M in Q3 2025. 95 funds tracked by Wall St. Rank hold IMRX as of Q1 2026.

Woodline Partners reported no remaining Immuneering position as of Q1 2026 after selling out during the quarter.
Woodline Partners sold 150,000 Immuneering shares in Q1 2026, an estimated $987K.
Woodline Partners first reported a position in Immuneering in Q3 2025 and held it in 2 quarters.
Woodline Partners's Immuneering position peaked at $1.05M in Q3 2025.
95 funds tracked by Wall St. Rank held Immuneering as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.